Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Relmada Therapeutics ( (RLMD) ) just unveiled an update.
Relmada Therapeutics announced that its Phase 3 Reliance II study for REL-1017, aimed at treating major depressive disorder, was deemed unlikely to meet its efficacy goals. Despite the setback, no new safety issues were found, and the company plans to reassess the data for potential next steps. Relmada remains focused on advancing its REL-P11 program for metabolic diseases and is well-capitalized with $54.1 million in cash.
Learn more about RLMD stock on TipRanks’ Stock Analysis page.
